These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35262569)

  • 1. Rationale and Design of the COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V) Randomized Clinical Trial: Hydroxychloroquine vs. Placebo in Non-Hospitalized Patients.
    Oliveira Junior HA; Ferri CP; Boszczowski I; Oliveira GBF; Cavalcanti AB; Rosa RG; Lopes RD; Azevedo LCP; Veiga VC; Berwanger O; Avezum Á
    Arq Bras Cardiol; 2022 Feb; 118(2):378-387. PubMed ID: 35262569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.
    Rodrigues C; Freitas-Santos RS; Levi JE; Senerchia AA; Lopes ATA; Santos SR; Siciliano RF; Pierrotti LC
    Int J Antimicrob Agents; 2021 Nov; 58(5):106428. PubMed ID: 34454044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban in Outpatients with Mild or Moderate COVID-19: Rationale and Design of the Study CARE (CARE - Coalition COVID-19 Brazil VIII).
    Oliveira GBF; Neves PDMM; Oliveira HA; Catarino DGM; Alves LBO; Cavalcanti AB; Rosa RG; Veiga VC; Azevedo LCP; Berwanger O; Lopes RD; Avezum Á
    Arq Bras Cardiol; 2023 Mar; 120(3):e20220431. PubMed ID: 37018790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
    Martins-Filho PR; Ferreira LC; Heimfarth L; Araújo AAS; Quintans-Júnior LJ
    Lancet Reg Health Am; 2021 Oct; 2():100062. PubMed ID: 34485970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.
    Johnston C; Brown ER; Stewart J; Karita HCS; Kissinger PJ; Dwyer J; Hosek S; Oyedele T; Paasche-Orlow MK; Paolino K; Heller KB; Leingang H; Haugen HS; Dong TQ; Bershteyn A; Sridhar AR; Poole J; Noseworthy PA; Ackerman MJ; Morrison S; Greninger AL; Huang ML; Jerome KR; Wener MH; Wald A; Schiffer JT; Celum C; Chu HY; Barnabas RV; Baeten JM;
    EClinicalMedicine; 2021 Mar; 33():100773. PubMed ID: 33681731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.
    González R; Goncé A; Gil MDM; Mazarico E; Ferriols-Pérez E; Toro P; Llurba E; Saéz E; Rodríguez-Zambrano MÁ; García-Otero L; López M; Santacruz B; Román MÁ; Payà A; Alonso S; Cruz-Lemini M; Pons-Duran C; Herrera LB; Chen H; Bardají A; Quintó L; Menendez C;
    Acta Obstet Gynecol Scand; 2024 Mar; 103(3):602-610. PubMed ID: 38098221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Test and treat COVID 65 plus - Hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of older patients with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Göpel S; Bethge W; Martus P; Kreth F; Iftner T; Joos S; Döbele S; Mordmüller B; Kremsner P; Ettrich T; Seufferlein T; Bitzer M; Malek N
    Trials; 2020 Jul; 21(1):635. PubMed ID: 32650818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE - Coalition V): A double-blind, multicentre, randomised, controlled trial.
    Avezum Á; Oliveira GBF; Oliveira H; Lucchetta RC; Pereira VFA; Dabarian AL; D O Vieira R; Silva DV; Kormann APM; Tognon AP; De Gasperi R; Hernandes ME; Feitosa ADM; Piscopo A; Souza AS; Miguel CH; Nogueira VO; Minelli C; Magalhães CC; Morejon KML; Bicudo LS; Souza GEC; Gomes MAM; Fo JJFR; Schwarzbold AV; Zilli A; Amazonas RB; Moreira FR; Alves LBO; Assis SRL; Neves PDMM; Matuoka JY; Boszczowski I; Catarino DGM; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O;
    Lancet Reg Health Am; 2022 Jul; 11():100243. PubMed ID: 35378952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial.
    Kaizer AM; Wild J; Lindsell CJ; Rice TW; Self WH; Brown S; Thompson BT; Hart KW; Smith C; Pulia MS; Shapiro NI; Ginde AA
    Trials; 2022 Apr; 23(1):273. PubMed ID: 35395957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.